CU20210075A7 - Arn terapéutico para el cáncer de próstata - Google Patents
Arn terapéutico para el cáncer de próstataInfo
- Publication number
- CU20210075A7 CU20210075A7 CU2021000075A CU20210075A CU20210075A7 CU 20210075 A7 CU20210075 A7 CU 20210075A7 CU 2021000075 A CU2021000075 A CU 2021000075A CU 20210075 A CU20210075 A CU 20210075A CU 20210075 A7 CU20210075 A7 CU 20210075A7
- Authority
- CU
- Cuba
- Prior art keywords
- immunogenic
- amino acid
- variant
- acid sequence
- immunogenic variant
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 abstract 15
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 239000012634 fragment Substances 0.000 abstract 5
- 102100021088 Homeobox protein Hox-B13 Human genes 0.000 abstract 3
- 102100028092 Homeobox protein Nkx-3.1 Human genes 0.000 abstract 3
- 101001041145 Homo sapiens Homeobox protein Hox-B13 Proteins 0.000 abstract 3
- 101000578249 Homo sapiens Homeobox protein Nkx-3.1 Proteins 0.000 abstract 3
- 102100038356 Kallikrein-2 Human genes 0.000 abstract 3
- 101710176220 Kallikrein-2 Proteins 0.000 abstract 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 abstract 3
- 102100038358 Prostate-specific antigen Human genes 0.000 abstract 3
- 102100035703 Prostatic acid phosphatase Human genes 0.000 abstract 3
- 108010043671 prostatic acid phosphatase Proteins 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/00116—Serine proteases, e.g. kallikrein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<p>La presente invención se refiere al campo del ARN terapéutico para el cáncer de próstata. Se describe una composición que comprende al menos un ARN que codifica las siguientes secuencias de aminoácidos: (i) una secuencia de aminoácidos que comprende calicreína-2 (KLK2), una variante inmunogénica de Ia misma, o un fragmento inmunogénico de Ia KLK2 o Ia variante inmunogénica de Ia misma; (ii) una secuencia de aminoácidos que comprende el antígeno prostático específico (PSA), una variante inmunogénica del mismo, o un fragmento inmunogénico del PSA o Ia variante inmunogénica del mismo; (iii) una secuencia de aminoácidos que comprende ácido prostático fosfatasa (PAP), una variante inmunogénica de Ia misma, o un fragmento inmunogénico de Ia PAP o Ia variante inmunogénica de Ia misma; (iv) una secuencia de aminoácidos que comprende Homeobox B13 (HOXB13), una variante inmunogénica del mismo, o un fragmento inmunogénico del HOXB13 o Ia variante inmunogénica del mismo; y (v) una secuencia de aminoácidos que comprende NK3 Homeobox 1 (NKX3-1), una variante inmunogénica del mismo, o un fragmento inmunogénico del NKX3-1 o Ia variante inmunogénica del mismo.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019056185 | 2019-03-12 | ||
| PCT/EP2020/056476 WO2020182869A1 (en) | 2019-03-12 | 2020-03-11 | Therapeutic rna for prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20210075A7 true CU20210075A7 (es) | 2022-04-07 |
Family
ID=69743256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000075A CU20210075A7 (es) | 2019-03-12 | 2020-03-11 | Arn terapéutico para el cáncer de próstata |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230114808A1 (es) |
| EP (1) | EP3917562A1 (es) |
| JP (1) | JP7740988B2 (es) |
| KR (1) | KR20210138586A (es) |
| CN (1) | CN113710267B (es) |
| AU (1) | AU2020233995A1 (es) |
| BR (1) | BR112021018039A2 (es) |
| CA (1) | CA3132908A1 (es) |
| CL (1) | CL2021002359A1 (es) |
| CO (1) | CO2021011892A2 (es) |
| CU (1) | CU20210075A7 (es) |
| IL (1) | IL285961A (es) |
| MA (1) | MA54868A (es) |
| MX (1) | MX2021010862A (es) |
| PH (1) | PH12021552023A1 (es) |
| SG (1) | SG11202108691TA (es) |
| WO (1) | WO2020182869A1 (es) |
| ZA (1) | ZA202106392B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182579A1 (en) * | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| CN112501201A (zh) * | 2021-02-07 | 2021-03-16 | 无锡市人民医院 | 一种用于治疗非小细胞肺癌的rna疫苗及其构建方法 |
| WO2023030635A1 (en) * | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| KR102850225B1 (ko) * | 2022-04-07 | 2025-09-18 | 엠큐렉스 주식회사 | 사스-코로나바이러스 2 감염증에 대한 rna 백신 |
| WO2024125597A1 (en) | 2022-12-14 | 2024-06-20 | Providence Therapeutics Holdings Inc. | Compositions and methods for infectious diseases |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| WO2025259931A1 (en) | 2024-06-14 | 2025-12-18 | Orbital Therapeutics, Inc. | Compositions and methods for rna circularization |
| WO2026006203A2 (en) | 2024-06-24 | 2026-01-02 | Orbital Therapeutics, Inc. | Compositions and methods for making circular rna |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2311951A1 (en) * | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| DE10347710B4 (de) * | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| KR20150090072A (ko) * | 2012-10-23 | 2015-08-05 | 카리스 라이프 사이언스 스위스 홀딩스 게엠베하 | 압타머 및 이의 용도 |
| CN105517566A (zh) * | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 用于治疗前列腺癌的组合物和疫苗 |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017081110A1 (en) * | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
| EP3445392A1 (en) * | 2016-04-22 | 2019-02-27 | CureVac AG | Rna encoding a tumor antigen |
| AU2017251983B2 (en) * | 2016-04-22 | 2023-07-20 | BioNTech SE | Methods for providing single-stranded RNA |
| TW202428301A (zh) * | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| AU2018316811B2 (en) * | 2017-08-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof |
-
2020
- 2020-03-11 EP EP20709210.7A patent/EP3917562A1/en active Pending
- 2020-03-11 JP JP2021554703A patent/JP7740988B2/ja active Active
- 2020-03-11 CA CA3132908A patent/CA3132908A1/en active Pending
- 2020-03-11 MA MA054868A patent/MA54868A/fr unknown
- 2020-03-11 SG SG11202108691TA patent/SG11202108691TA/en unknown
- 2020-03-11 BR BR112021018039A patent/BR112021018039A2/pt unknown
- 2020-03-11 US US17/310,773 patent/US20230114808A1/en active Pending
- 2020-03-11 CN CN202080013878.2A patent/CN113710267B/zh active Active
- 2020-03-11 AU AU2020233995A patent/AU2020233995A1/en active Pending
- 2020-03-11 PH PH1/2021/552023A patent/PH12021552023A1/en unknown
- 2020-03-11 WO PCT/EP2020/056476 patent/WO2020182869A1/en not_active Ceased
- 2020-03-11 MX MX2021010862A patent/MX2021010862A/es unknown
- 2020-03-11 CU CU2021000075A patent/CU20210075A7/es unknown
- 2020-03-11 KR KR1020217027838A patent/KR20210138586A/ko not_active Ceased
-
2021
- 2021-08-30 IL IL285961A patent/IL285961A/en unknown
- 2021-09-01 ZA ZA2021/06392A patent/ZA202106392B/en unknown
- 2021-09-09 CL CL2021002359A patent/CL2021002359A1/es unknown
- 2021-09-10 CO CONC2021/0011892A patent/CO2021011892A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022525103A (ja) | 2022-05-11 |
| SG11202108691TA (en) | 2021-09-29 |
| BR112021018039A2 (pt) | 2021-11-23 |
| ZA202106392B (en) | 2023-06-28 |
| MX2021010862A (es) | 2021-10-22 |
| JP7740988B2 (ja) | 2025-09-17 |
| KR20210138586A (ko) | 2021-11-19 |
| CA3132908A1 (en) | 2020-09-17 |
| CL2021002359A1 (es) | 2022-04-08 |
| CO2021011892A2 (es) | 2022-01-28 |
| AU2020233995A1 (en) | 2021-09-23 |
| US20230114808A1 (en) | 2023-04-13 |
| CN113710267A (zh) | 2021-11-26 |
| CN113710267B (zh) | 2025-05-09 |
| PH12021552023A1 (en) | 2022-09-12 |
| IL285961A (en) | 2021-10-31 |
| WO2020182869A1 (en) | 2020-09-17 |
| MA54868A (fr) | 2021-12-08 |
| EP3917562A1 (en) | 2021-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021011892A2 (es) | Arn terapéutico para el cáncer de próstata | |
| PH12021500014A1 (en) | Fused ring compounds | |
| PE20210452A1 (es) | Inhibidores de la arginasa | |
| CL2017001968A1 (es) | Ácidos 3-alquil-4-amido-bicíclico [4.5.0] hidroxámico como inhibidores de hdac | |
| EP4487869A3 (en) | Rna encoding a tumor antigen | |
| ECSP18087352A (es) | Formulaciones de un inhibidor de lsd1 | |
| CY1116458T1 (el) | Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων | |
| JP2016540889A5 (es) | ||
| JOP20170170A1 (ar) | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق | |
| MX389805B (es) | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. | |
| UY36554A (es) | ARNi VARIANTE | |
| CU20210097A7 (es) | Arn terapéutico para cáncer de ovario | |
| MX2021007241A (es) | Acido ribonucleico (arn) que codifica para una proteina. | |
| CL2021000950A1 (es) | Anticuerpos contra el lif y usos de los mismos (divisional de la solicitud no. 201901717) | |
| WO2018065623A3 (en) | Immunogenic compounds for cancer therapy | |
| CL2019003393A1 (es) | Virus oncolíticos y método. | |
| MX2021002250A (es) | Dominio de nucleasa novedoso y uso del mismo. | |
| CR8519A (es) | Nuevos pirrolocarbazoles fusionados | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser | |
| WO2018065625A3 (en) | Immunogenic compounds for cancer therapy | |
| CO2020000231A2 (es) | Composiciones inmunogénicas que comprenden cea muc1 y tert | |
| PY2285025A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| CL2017003000A1 (es) | Conjugados fluorescentes | |
| EA202100145A1 (ru) | Применение гуанабенза |